BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10504054)

  • 21. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.
    Tsuboi R; Rifkin DB
    Int J Cancer; 1990 Jul; 46(1):56-60. PubMed ID: 2142142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
    Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC
    J Vasc Surg; 1997 Jan; 25(1):157-64. PubMed ID: 9013920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different response to retinoic acid of two teratocarcinoma cell lines.
    Wan YJ; Wang L; Wu TC
    Exp Cell Res; 1995 Aug; 219(2):392-8. PubMed ID: 7543852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
    Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
    Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines.
    Xu XC; Liu X; Tahara E; Lippman SM; Lotan R
    Cancer Res; 1999 May; 59(10):2477-83. PubMed ID: 10344761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinoic acid differentially regulates retinoic acid receptor-mediated pathways in the Hep3B cell line.
    Wan YJ; Cai Y; Magee TR
    Exp Cell Res; 1998 Jan; 238(1):241-7. PubMed ID: 9457077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines.
    Uchida D; Kawamata H; Nakashiro K; Omotehara F; Hino S; Hoque MO; Begum NM; Yoshida H; Sato M; Fujimori T
    Br J Cancer; 2001 Jul; 85(1):122-8. PubMed ID: 11437413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redox control of retinoic acid receptor activity: a novel mechanism for retinoic acid resistance in melanoma cells.
    Demary K; Wong L; Liou JS; Faller DV; Spanjaard RA
    Endocrinology; 2001 Jun; 142(6):2600-5. PubMed ID: 11356710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator.
    Canipari R; O'Connell ML; Meyer G; Strickland S
    J Cell Biol; 1987 Aug; 105(2):977-81. PubMed ID: 3040774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3.
    Liu DF; Rabbani SA
    Prostate; 1995 Nov; 27(5):269-76. PubMed ID: 7479394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator.
    Tiberio A; Farina AR; Tacconelli A; Cappabianca L; Gulino A; Mackay AR
    Int J Cancer; 1997 Nov; 73(5):740-8. PubMed ID: 9398056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of avian urokinase and tissue-type plasminogen activator messenger ribonucleic acid during follicle development and atresia.
    Johnson AL; Bridgham JT; Anthony RV
    Biol Reprod; 1997 Mar; 56(3):581-8. PubMed ID: 9047000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
    Baker EA; Bergin FG; Leaper DJ
    Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
    Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
    Br J Rheumatol; 1992; 31 Suppl 1():19-26. PubMed ID: 1555050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
    Lyon PB; See WA; Xu Y; Cohen MB
    Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines.
    Albrechtsson E; Ohlsson B; Axelson J
    Pancreas; 2002 Jul; 25(1):49-56. PubMed ID: 12131771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.